Peter Kuhn

Peter Kuhn, PhD, is University Professor at USC and holds chairs as the Dean’s Professor of Biological Sciences, Professor of Medicine, Urology, Aerospace & Mechanical Engineering, and Biomedical Engineering. He is the Director of the USC Michelson Convergent Science Institute in Cancer (CSI-Cancer) and the multi-institutional Convergent Science Cancer Consortium. He holds a chair as Honorary Professor of Cancer Science at the University of Manchester in the United Kingdom.   

He is a scientist, educator and entrepreneur with a career long commitment in personalized medicine and individualized cancer patient care. The first product from technology developed by Dr. Kuhn became available for prostate cancer care in 2016 and breast cancer in 2021.  Dr. Kuhn’s strategy is to advance our understanding of the human body to improve the human condition for those affected by cancer. His research is shedding new light at how cancer spreads through the body and evolves over time. This new science will lead to a personalized care strategy that is biologically informed and clinically actionable.  Dr. Kuhn has published over 300 peer reviewed manuscripts and his work has been cited over 30k times. 

Dr. Kuhn is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 and his Ph.D. in 1995. He then moved to Stanford University where he joined the faculties of Medicine and Accelerator Physics. From 2002 to 2014 he established the Physics Oncology program at Scripps Research in La Jolla, CA before joining USC in 2014. He has published over 200 peer scientific articles and patents as a result of his research. He founded Epic Sciences, Inc. in 2009 to develop cancer diagnostic products. In June 2016, Epic Sciences’ first CLIA certified LDT became available for patient care following the publication of clinical data demonstrating its predictive power.